Raymond Debbane insider trades: Lexicon Pharmaceuticals (LXRX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Raymond reports to the SEC
and 3 more companies
Open-market buys and sales
25 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | LXRX | ↑ Buy | 2,000 | $1.49 | $3K | Direct | Feb 27, 2026 (2d) |
| Feb 20, 2026 | LXRX | ↑ Buy | 150,000 | $1.47 | $220K | Direct | Feb 23, 2026 (3d) |
| Feb 18, 2026 | LXRX | ↑ Buy | 268,497 | $1.31 | $353K | Direct | Feb 18, 2026 (0d) |
| Feb 2, 2026 | LXRX | ↑ Buy | 1,538,462 | $1.30 | $2.0M | Indirect | Feb 4, 2026 (2d) |
| Dec 10, 2024 | SRRK | ↓ Sell | 1,600,000 | $41.65 | $66.6M | Direct | Dec 12, 2024 (2d) |
| Nov 25, 2024 | SRRK | ↓ Sell | 409,433 | $38.49 | $15.8M | Direct | Nov 27, 2024 (2d) |
| Aug 8, 2024 | GLYC | ↓ Sell | 322,361 | $0.19 | $61K | Direct | Aug 9, 2024 (1d) |
| Aug 6, 2024 | GLYC | ↓ Sell | 220,255 | $0.19 | $41K | Direct | Aug 7, 2024 (1d) |
| Aug 2, 2024 | GLYC | ↓ Sell | 349,764 | $0.20 | $71K | Direct | Aug 5, 2024 (3d) |
| Jul 30, 2024 | GLYC | ↓ Sell | 1,379,119 | $0.23 | $315K | Direct | Jul 30, 2024 (0d) |
| Oct 12, 2023 | LXRX | ↑ Buy | 1,000,000 | $1.10 | $1.1M | Direct | Oct 12, 2023 (0d) |
| Nov 10, 2022 | WW | ↑ Buy | 75,000 | $4.27 | $320K | Direct | Nov 15, 2022 (5d) |
| Aug 5, 2022 | LXRX | ↑ Buy | 147,390 | $2.50 | $368K | Indirect | Aug 9, 2022 (4d) |
| Aug 1, 2022 | LXRX | ↑ Buy | 982,600 | $2.50 | $2.5M | Indirect | Aug 1, 2022 (0d) |
| Aug 1, 2022 | LXRX | ↑ Buy | 982,600 | $2.50 | $2.5M | By Invus US Partners LLC | Aug 1, 2022 (0d) |
| Sep 16, 2019 | LXRX | ↑ Buy | 103,042 | $2.69 | $278K | Direct | Sep 17, 2019 (1d) |
| Sep 13, 2019 | LXRX | ↑ Buy | 197,473 | $2.40 | $475K | Direct | Sep 17, 2019 (4d) |
| Mar 1, 2016 | WTW | ↑ Buy | 83,125 | $12.03 | $1.0M | Direct | Mar 3, 2016 (2d) |
| Dec 12, 2014 | LXRX | ↑ Buy | 150,000 | $0.88 | $132K | Indirect | Dec 12, 2014 (0d) |
| Dec 10, 2014 | LXRX | ↑ Buy | 315,896 | $0.90 | $285K | Indirect | Dec 10, 2014 (0d) |
| Oct 23, 2012 | LXRX | ↑ Buy | 3,000,000 | $2.25 | $6.8M | Indirect | Oct 25, 2012 (2d) |
| Mar 19, 2010 | LXRX | ↑ Buy | 94,270,206 | $1.15 | $108.4M | Indirect | Mar 19, 2010 (0d) |
| Oct 15, 2009 | LXRX | ↑ Buy | 15,455,145 | $1.50 | $23.2M | Indirect | Oct 15, 2009 (0d) |
| Aug 23, 2008 | LXRX | ↑ Buy | 50,824,986 | $4.04 | $205.5M | Indirect | Aug 24, 2007 (0d) |
| Apr 30, 2008 | LXRX | ↑ Buy | 669,052 | $2.00 | $1.3M | Indirect | May 2, 2008 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LXRX insiders
Open-market trades in the last 12 months
About Raymond Debbane's insider trades
Raymond Debbane is a director at Lexicon Pharmaceuticals (LXRX). Since Apr 30, 2008, Raymond has reported 19 open-market purchases worth $356.6M and 6 sales worth $82.9M on SEC Form 4. In the last 12 months: 4 buys ($2.6M).
Their filings also include grants and awards (104 filings), option exercises (9 filings), gifts (2 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LXRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.